Correction to: iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy.

Trials

Department of Viroscience, Erasmus MC, Room Ee-1726, P.O. Box 2040, 3000, CA, Rotterdam, The Netherlands.

Published: December 2019

Following publication of the original article [1], we have been notified that end note would need to be adjusted.

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909442	PMC
http://dx.doi.org/10.1186/s13063-019-3940-0	DOI Listing

Publication Analysis

correction ihivarna

ihivarna phase

phase iia

iia randomized

randomized placebo-controlled

placebo-controlled double-blinded

double-blinded trial

trial evaluate

evaluate safety

safety immunogenicity

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!